Navigation Links
Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
Date:4/30/2008

First batch of bluetongue Bovilis BTV8 vaccine released to supply Northern

European countries

BOXMEER, Netherlands, April 30 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health (NYSE: SGP) released the first batch of Bovilis BTV8 vaccine against bluetongue to supply in Northern Europe. The animal health company, combining after the acquisition in 2007 the strength of Intervet and Schering-Plough Animal Health, is not only the world market leader in the production of animal health vaccines, but also one of the world's leaders in the field of animal health.

"Within the animal health sector, there has been a recent emphasis on prevention rather than treatment," says Ruurd Stolp, D.V.M., Ph.D., Senior Vice President and President Global Animal Health. "Our goal is to develop innovative vaccines that address unmet needs and improve disease protection as well as the duration of that protection. When animal diseases are not prevented, the social economic and environmental costs to humans are potentially significant." One prominent example is bluetongue, a devastating disease of ruminants that emerged in Northern Europe since the summer of 2006. The combined animal health unit is uniquely positioned to respond to this need and to deliver effective and timely care.

Intervet/Schering-Plough Animal Health has now released the first batch of bluetongue vaccine for sheep and cattle, Bovilis BTV8, fulfilling firm orders received from a number of countries within Europe. Stolp: "We put great effort into the development of our safe and efficacious Bovilis BTV8 vaccine to meet the urgent need as quickly as possible and we are pleased that production is on track, so that we are able to deliver the first amounts of vaccine before the actual start of the "midge season".

Intervet/Schering-Plough Animal Health has developed the Bovilis BTV8 vaccine in a very short period of time. It has been two years since the emergence of the virus in Northern Europe in 2006. The company supplies Bovilis BTV8 vaccine to a number of European countries. At this moment the supply is in balance with the confirmed orders and undecided tender applications.

Stolp: "While the development of effective disease prevention is important, veterinarians also need innovative treatments for a wide variety of diseases. The combination strengthens our innovation-driven, science-centered approach and allows us to complete our broad pharmaceutical segment and to focus on growth opportunities, geographically or in certain product categories and key species segments. As a global leader in animal vaccines, we are concerned with the global health issues and are in a position to take a leadership role in helping to control some threatening infectious diseases."

Schering-Plough's animal health business, with products originating from both Intervet and Schering-Plough Animal Health (SPAH), offers pharmaceuticals and vaccines for companion animals that enable pets and humans to enjoy their time together, as well as a comprehensive portfolio for livestock to help keep them healthy and ensure a safe, wholesome food supply.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Intervet/Schering-Plough Animal Health
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
2. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. Odyssey Thera Granted U.S. Patent for Animal Imaging
5. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
6. Researchers use magnetism to target cells to animal arteries
7. Smithfield Foods, Inc. Statement Regarding Animal Cloning
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... study that validated the ability of the Aethlon Hemopurifier® ... increased mortality in immune-suppressed sepsis patients and also contribute ... The objective of the study was to validate the ... virus (EBV) and Herpes Simplex virus 1 (HSV1) by ...
(Date:2/22/2017)... PARK, N.C., Feb. 22, 2017  United Therapeutics Corporation ... financial results for the fourth quarter and year ... financial results reflect continued growth as net revenues ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... ability to develop and advance our growing product ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Liquid Biopsy System , a fully automated benchtop system for collecting intact circulating ... is being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 ...
(Date:2/21/2017)... , ... February 21, 2017 ... ... Life -Sciences division, Treximo will pair its $200M operational capacity with its ... and project management in areas affecting quality and operational management. With ...
Breaking Biology Technology:
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):